Endo announces update on Phase III-program for Orexo´s pain product Rapinyl™

Endo announces update on Phase III-program for Orexo´s pain product Rapinyl™

On November 1 2007, Orexo´s licensing partner Endo Pharmaceuticals has, in
connection with the announcement of their Interim Report, left the following
information:

“RAPINYL™. The company announced that, due to the continued challenge of
recruiting cancer patients in its Phase III placebo-controlled efficacy trial of
this sublingual fentanyl tablet being studied for the treatment of breakthrough
cancer pain, it has decided that it will conduct an interim statistical analysis
of this trial. This interim analysis will be conducted as soon as possible when
a predetermined number of patients (based upon a power calculation) with
evaluable data have completed the trial. The company will provide further
updates when this analysis is completed.”

For further information, please contact: 
Zsolt Lavotha, President and CEO, Orexo AB 
+46 (0)18 780 88 12, e-mail: zsolt.lavotha@orexo.se 

Claes Wenthzel, Executive Vice President and CFO, Orexo AB 
+46 (0)18 780 88 44, e-mail: claes.wenthzel@orexo.se

TO THE EDITORS 

About Orexo 

Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo´s drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets. 

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase, one in clinical phase I, one in
formulation phase and two in early development phase. 

Orexo is listed on the OMX Nordic List Mid Cap (ticker: ORX). 

www.orexo.com